Civil Law And Synthetic Biology Legal Ownership And Liability In Engineered Life In Uae .

1. Introduction

Synthetic biology is an emerging scientific field that combines biology, genetic engineering, biotechnology, computational science and engineering to design, modify or construct biological systems.

It involves the creation or modification of:

Genetically engineered microorganisms.

Synthetic DNA and RNA sequences.

Artificial biological circuits.

Engineered cells and tissues.

Synthetic organisms.

Gene-editing technologies.

Laboratory-developed biological materials.

Engineered enzymes and biological products.

Synthetic biology creates important civil-law questions concerning ownership, intellectual property, contractual rights, liability, compensation, informed consent and responsibility for biological risks.

In the UAE, these issues are particularly relevant to biotechnology companies, pharmaceutical manufacturers, universities, research institutions, hospitals, laboratories and investors.

For example, suppose a UAE biotechnology company develops a genetically engineered microorganism for pharmaceutical manufacturing. The development may involve:

Scientists who design the genetic sequence.

A university that finances the research.

A company that owns the laboratory equipment.

Investors who finance commercial development.

A patent applicant claiming intellectual property rights.

A manufacturer using the organism commercially.

Regulatory authorities supervising biological safety.

The central legal question is: Who owns the engineered biological material, who controls its use, and who bears responsibility if it causes harm?

These questions cannot be answered by applying property law alone. They require an integrated examination of UAE civil law, intellectual property law, biosafety regulation, commercial contracts and liability principles.

2. Meaning and legal nature of synthetic biology

Synthetic biology differs from conventional biotechnology because it involves the systematic design and engineering of biological systems rather than merely using naturally occurring biological processes.

Advance Your Research with NextGenSeek's Cutting-Edge NGS Data Analysis Services - NextGenSeek: custom NGS analysis

 

 

Synthetic Biology Services | SBS Genetech – Strain Development, Bioprocess Optimization & Scale-Up

 

 

Super-precise CRISPR tool enters US clinical trials for the first time

 

9

 

Its main legal categories include:

CategoryExampleMain legal question
Synthetic DNAArtificially designed genetic sequencesPatentability and ownership
Engineered organismsModified bacteriaBiological safety and liability
Engineered cellsModified human or animal cellsConsent and material ownership
Synthetic enzymesLaboratory-designed proteinsIntellectual property
Gene-editing systemsCRISPR-based technologiesPatent rights and responsibility
Biological productsEngineered pharmaceuticalsProduct liability
Research datasetsGenetic and genomic informationData protection and contractual control

Synthetic biology can create assets that have scientific, commercial and medical value. However, legal ownership of a physical biological sample does not automatically establish ownership of every genetic sequence, invention, dataset or intellectual property right associated with it.

3. UAE legislative framework governing synthetic biology

The UAE does not have one comprehensive statute specifically entitled a Synthetic Biology Act. Instead, synthetic biology is regulated through several interconnected federal laws.

The most important legislation includes:

LegislationMain subject
Federal Law No. 9 of 2020Biosafety of genetically modified organisms
Cabinet Resolution No. 84 of 2022Executive Regulation of GMO biosafety
Federal Law No. 8 of 2021Access to genetic resources and benefit-sharing
Cabinet Resolution No. 32 of 2023Executive Regulation of genetic resources legislation
Federal Decree-Law No. 49 of 2023Regulation of the use of the human genome
Federal Law No. 11 of 2021Industrial property and patent protection
Federal Decree-Law No. 45 of 2021Personal Data Protection
Federal Decree-Law No. 25 of 2025Civil Transactions Law

These laws address different dimensions of synthetic biology: biological safety, genetic-resource access, human dignity, intellectual property, privacy and civil compensation.

A. Federal Law No. 9 of 2020: Biosafety of GMOs

Most important biosafety legislation

Federal Law No. 9 of 2020 concerning the Biosafety of Genetically Modified Organisms and Their Products is particularly important for synthetic biology.

It regulates activities involving genetically modified organisms and their products, including relevant research, development, manufacture, production, transportation, importation and circulation.

Its objectives include:

Protecting human health.

Protecting environmental safety.

Preserving biodiversity and genetic resources.

Regulating the development and commercial use of GMOs.

Preventing or reducing biological risks.

Establishing liability for damage caused by regulated activities.

The law requires relevant approvals and permits for regulated activities. The competent authorities also have powers concerning inspection, monitoring and suspension of unauthorised activities.

Application to synthetic biology: An engineered microorganism developed in a UAE laboratory may fall within this law if it satisfies the statutory definition of a GMO.

However, not every synthetic biological product automatically qualifies as a GMO. Its biological characteristics and method of development must be examined.

B. Article 16 – Civil liability for biological damage

This is one of the most important provisions for the present topic.

Article 16 of Federal Law No. 9 of 2020 specifically addresses civil liability.

It provides that the following persons are liable for damage caused by the relevant regulated activities:

Importers.

Exporters.

Persons circulating GMOs.

Developers.

Manufacturers.

Producers.

Transporters.

The provision covers damage caused through importing, exporting, re-exporting, transiting, circulating, developing, manufacturing or producing GMOs or their products.

UAE Legislation+1

 

Legal significance:

Unlike an ordinary negligence claim, Article 16 identifies liability by reference to participation in specified GMO-related activities and damage caused by those activities.

It therefore provides a special statutory basis for risk-based civil responsibility.

For example, if a company develops a genetically engineered microorganism and it escapes from a controlled facility, causing environmental damage, the developer and other relevant statutory actors may face civil liability.

The claimant must still establish the relevant damage and causal connection. The precise application of defences and the relationship between the special law and general civil law must be examined in the individual case.

C. Cabinet Resolution No. 84 of 2022

This resolution provides the executive framework for implementing Federal Law No. 9 of 2020.

It addresses regulatory procedures, permits, approvals and controls associated with GMO activities.

Its importance for synthetic biology lies in the fact that biological safety is not simply a matter of contractual compliance.

A biotechnology company must also comply with the applicable regulatory requirements concerning the handling, development, movement and use of genetically modified organisms.

UAE Legislation+1

 

D. Federal Law No. 8 of 2021: Access to genetic resources

Federal Law No. 8 of 2021 regulates access to genetic resources and their derivatives and establishes fair and equitable benefit-sharing requirements.

It is especially relevant to synthetic biology research involving biological materials obtained from the UAE's natural environment.

The legislation covers genetic resources originating from:

Plants.

Animals.

Microorganisms.

Other biological sources containing genetic material.

It establishes requirements for obtaining permits and sharing benefits arising from utilisation.

Importantly, Article 3 excludes human genetic resources from this particular law. Human genetic material is addressed through the separate human-genome regulatory framework.

Article 4 requires an appropriate permit for access to regulated genetic resources, while Article 9 addresses benefit-sharing.

littdb.sfo2.cdn.digitaloceanspaces.com+1

 

Example:

A biotechnology company obtains microorganisms from a UAE desert ecosystem and uses their genetic characteristics to develop an industrial enzyme.

The company must consider:

Whether the material is a regulated genetic resource.

Whether access permission is required.

Whether import or export approval is necessary.

Whether a benefit-sharing agreement applies.

Whether resulting commercial innovations are subject to contractual or intellectual property restrictions.

E. Federal Decree-Law No. 49 of 2023: Regulation of the human genome

This legislation is particularly important where synthetic biology involves human genetic material.

It regulates the use of the human genome throughout the UAE, including free zones.

Its main objectives include:

Protecting human dignity.

Protecting genetic privacy.

Ensuring safe use of genomic information.

Regulating genetic screening and research.

Protecting individuals against discriminatory use of genetic information.

Important provisions include:

Article 16 – Prohibition of certain genomic alterations

The legislation prohibits the use of human genes and genomes to alter the genomic structure of people for purposes such as improving lineage, purifying the human race or other prohibited purposes.

Article 21 – Use in civil liability proceedings

Genomic or genetic screening cannot simply be requested to detect symptoms or diagnose a particular disease for calculating compensation, except pursuant to a judicial order or ruling.

Article 25 – Genetic confidentiality

Genomic and genetic data must remain confidential and may only be disclosed or circulated in legally permitted circumstances.

Article 28 – Licensing

Facilities undertaking regulated human-genome services must obtain the relevant health-authority licence.

These provisions are particularly important for synthetic biology companies working with engineered human cells, genomic research, gene editing and biobanking.

littdb.sfo2.cdn.digitaloceanspaces.com+1

 

F. Federal Law No. 11 of 2021: Intellectual property ownership

This legislation governs industrial property rights, including patents, utility certificates and undisclosed information.

Article 5 establishes the principal requirements for patent protection:

Novelty.

Inventive step.

Industrial applicability.

Article 7 establishes exclusions from patentability, including certain biological inventions, natural materials and inventions harmful to human health or the environment.

Importantly, the law provides an exception for microbiological processes and their products within the applicable statutory and regulatory framework.

Article 8 addresses determination of inventorship and joint inventions.

Article 10 addresses inventions created under employment or assignment agreements. In general, the employer is entitled to an invention created under such an agreement, unless the parties agree otherwise, subject to the employee's statutory rights, including additional compensation in qualifying circumstances.

Application: A novel engineered microorganism or synthetic biological manufacturing process may qualify for patent protection if the statutory requirements are satisfied and no exclusion applies.

However, the mere discovery of a naturally occurring genetic sequence does not automatically establish patent ownership.

WIPO+2

 

4. Ownership of synthetic biological materials under UAE civil law

Ownership is one of the most complex issues in synthetic biology.

A single research project can involve several different legally protected interests.

A. Ownership of physical biological materials

Physical materials may include:

Engineered bacteria.

Genetically modified cells.

Laboratory samples.

Synthetic tissue.

Biological cultures.

Engineered enzymes.

Ownership or lawful possession of these materials must be examined through the relevant property, contractual and regulatory rules.

For example, a university may own laboratory equipment and hold lawful custody of biological samples, while the intellectual property rights in a newly developed process belong to a researcher or employer under the applicable agreements and patent legislation.

Possession of a sample does not automatically establish ownership of every invention derived from it.

B. Ownership of synthetic DNA sequences

A synthetic DNA sequence may have several legal dimensions:

The physical DNA molecule.

The information represented by its nucleotide sequence.

A technical invention involving the sequence.

Copyright or database interests in associated research materials, where applicable.

Confidential know-how concerning its development.

These interests must be analysed separately.

For example, a company may own a physical synthetic DNA sample without necessarily possessing exclusive rights over the underlying scientific information.

C. Ownership of engineered organisms

The legal treatment of an engineered organism depends on the nature of the organism and the applicable legislation.

Relevant considerations include:

Who created it?

Who supplied the original biological material?

Was the organism developed under an employment agreement?

Was it created using public or university funding?

Does a patent cover the relevant invention?

Were the necessary biological-safety approvals obtained?

Are there benefit-sharing obligations?

Ownership cannot be used to avoid mandatory biosafety requirements.

D. Ownership of human biological materials

Human biological material raises different issues because of human dignity, consent, confidentiality and personal rights.

A person providing a blood, tissue or genetic sample does not automatically transfer all legal rights concerning that material merely by handing it to a laboratory.

The legal analysis must consider:

Valid consent.

Permitted research purposes.

Applicable licensing.

Confidentiality.

Restrictions on further use.

Genetic-data protection.

The terms of any biobank agreement.

The UAE Human Genome Law provides an important special framework for these issues.

5. Ownership of synthetic biology inventions and patents

Patent ownership is especially important because synthetic biology can produce commercially valuable inventions.

A. Researcher ownership

A researcher may be recognised as the inventor where they make the legally relevant inventive contribution.

The right to be identified as inventor is distinct from the right to commercially exploit the patent.

B. Employer ownership

Where an invention is created pursuant to an employment or assignment agreement, Article 10 of Federal Law No. 11 of 2021 generally allocates the invention rights to the employer unless otherwise agreed.

The employee may nevertheless have statutory entitlement to additional compensation where the invention's economic value substantially exceeds the parties' expectations.

C. Joint ownership

Where several researchers contribute to the inventive concept, joint inventorship may arise.

For example, a synthetic biology project may involve:

A genetic engineer designing a biological circuit.

A molecular biologist developing the organism.

A computational scientist developing a novel technical method.

Their respective contributions must be examined. Merely assisting with laboratory work does not automatically establish joint inventorship.

D. University-funded research

University research creates additional ownership questions.

The relevant documents may include:

Employment agreements.

Research funding agreements.

Sponsored research contracts.

Technology-transfer agreements.

Patent assignment documents.

Confidentiality agreements.

A university's funding of research does not, by itself, answer every question concerning inventorship, ownership and licensing.

6. Civil liability for harm caused by synthetic biology

Civil liability is one of the most important dimensions of this subject.

Synthetic biology can produce risks that extend beyond the laboratory.

Examples include:

Accidental release of genetically engineered organisms.

Environmental contamination.

Damage to agricultural crops.

Biological contamination of water.

Harm caused by defective biological products.

Medical injury resulting from engineered cell therapies.

Unauthorised genetic manipulation.

Damage arising from defective laboratory procedures.

The UAE legal framework can impose responsibility through both special biosafety legislation and general civil-liability principles.

A. Developer liability

A biotechnology developer may be responsible where damage is caused by its regulated development activities.

Under Article 16 of Federal Law No. 9 of 2020, developers of GMOs are expressly included among the persons potentially liable for damage.

B. Manufacturer liability

A manufacturer may face responsibility where a defective or unsafe biological product causes harm.

Potential situations include:

Contaminated biological products.

Defective engineered enzymes.

Unsafe genetically modified agricultural products.

Improperly manufactured biological medicines.

C. Laboratory liability

A laboratory may face contractual or civil responsibility where harm results from:

Inadequate containment.

Failure to follow safety procedures.

Negligent handling.

Improper storage.

Unauthorised release.

Failure to maintain accurate biological records.

D. Research institution liability

A research institution may face responsibility where its employees or agents cause damage in circumstances engaging the institution's own statutory or civil liability.

The exact responsibility depends on the employment relationship, supervision, contractual arrangements and applicable law.

E. Transporter and distributor liability

A transporter or distributor may also fall within Article 16 of the GMO Biosafety Law.

For example, if a company transports genetically engineered microorganisms without adequate safeguards and the material escapes, the statutory liability framework may become applicable.

7. Strict liability and risk-based responsibility in synthetic biology

Synthetic biology is particularly suitable for examining risk-based civil responsibility because biological damage may be difficult to reverse.

The UAE's GMO Biosafety Law is important because Article 16 expressly identifies categories of persons liable for damage caused by specified GMO-related activities.

Consider this hypothetical situation:

A UAE biotechnology company develops an engineered bacterium for industrial waste treatment. During commercial transportation, the organism escapes and contaminates a neighbouring agricultural property.

The potential civil claims may involve:

The developer.

The manufacturer.

The transporter.

The distributor.

Other persons whose activities caused or contributed to the damage.

The claimant would need to establish the relevant biological damage and causal connection.

The legal analysis should also consider whether the organism falls within the GMO legislation and whether other special environmental or agricultural laws apply.

Important distinction: Article 16 provides a specific statutory liability framework. It should not be interpreted as imposing automatic liability on every person associated with biotechnology regardless of causation, damage or the statutory scope.

8. Liability for environmental damage

Environmental damage is a major concern in synthetic biology.

Potential risks include:

Escape of engineered microorganisms.

Genetic contamination of natural populations.

Damage to agricultural biodiversity.

Contamination of water resources.

Disruption of ecological systems.

Uncontrolled biological multiplication.

The UAE's environmental and biosafety framework aims to protect human health, the environment and biological diversity.

A biotechnology company may face several forms of legal exposure:

Form of responsibilityPossible consequence
Civil liabilityCompensation for proven damage
Regulatory liabilitySuspension or revocation of permits
Administrative liabilityFines or closure measures where authorised
Contractual liabilityClaims by customers, investors or research partners
Environmental responsibilityRestoration or remediation obligations where applicable
Criminal responsibilityProsecution where statutory offences are established

Example

A company releases an engineered microorganism into agricultural soil without the necessary approval.

The organism spreads beyond the intended location and damages neighbouring crops.

Possible legal issues include:

Unauthorised release.

Failure to comply with biosafety conditions.

Damage to agricultural property.

Loss of agricultural income.

Remediation expenses.

Responsibility of developers, manufacturers and distributors.

9. Human genetic engineering, consent and civil responsibility

Human synthetic biology creates particularly sensitive legal questions.

The UAE Human Genome Law provides restrictions on the use of human genes and genomes.

Three principles are particularly important.

First: Human dignity.

Scientific development cannot be treated as unrestricted authority to alter human genetic characteristics.

Second: Informed consent.

Research involving voluntary genomic screening and other regulated procedures must comply with statutory consent requirements.

Third: Genetic privacy.

Genetic information is confidential and must be handled according to applicable legislation.

Example: Unauthorised genetic research

Suppose a laboratory uses a patient's genetic sample for a research project beyond the authorised purpose.

Potential claims may involve:

Violation of consent requirements.

Unauthorised use of biological material.

Breach of confidentiality.

Personal-data violations.

Contractual liability.

Compensation for legally recognised harm.

The laboratory's possession of the biological sample would not, by itself, authorise unrestricted research or commercial exploitation.

10. Synthetic biology and pharmaceutical product liability

Synthetic biology is increasingly important in pharmaceutical research and medicine.

Engineered biological systems may be used to develop:

Insulin and other therapeutic proteins.

Vaccines.

Gene therapies.

Engineered immune cells.

Biological diagnostic products.

Personalised medicines.

These products may create civil liability where defective manufacturing, inadequate testing or improper administration causes injury.

A manufacturer, pharmaceutical facility, healthcare provider or other responsible party may face different forms of liability.

The relevant legal framework may include the GMO Biosafety Law, human-genome legislation, medical-product legislation and the applicable medical-liability framework.

A crucial distinction must be made between manufacturing defects, regulatory non-compliance, medical negligence and adverse outcomes that occur despite appropriate professional care.

11. Important UAE judicial decisions and case laws

Important research qualification: Synthetic biology is a relatively new legal field. I could not identify six published UAE judgments directly deciding ownership or civil liability for synthetic organisms or synthetic DNA. It would be misleading to invent such precedents.

The following seven genuine UAE judicial authorities are therefore presented as analogical authorities. They address medical injury, institutional responsibility, causation, defective performance, compensation and exceptional events. They help explain how UAE courts may approach future synthetic biology disputes, but they are not synthetic-biology judgments.

Case 1. Dubai Court of Cassation – Civil Appeal No. 62 of 2025

Important medical liability authority

Judgment date: 27 February 2025.

Subject: Medical negligence, causation and compensation.

Facts:

A child was treated at a private hospital for meningitis. The child's father alleged that delayed treatment and inadequate medical intervention caused serious neurological injuries.

The Higher Medical Liability Committee examined the treatment and identified medical error and resulting harm.

Judicial principles:

Medical liability requires specialist assessment under the applicable medical-liability legislation.

The relationship between the medical error and the resulting injury must be examined.

The relevant limitation period must be assessed according to the legally applicable knowledge requirements.

Courts must identify and assess each head of damage separately.

Employers may face responsibility for their employees' legally attributable conduct.

Application to synthetic biology:

Suppose an engineered cell therapy causes permanent neurological injury because a laboratory failed to identify a serious biological defect.

This judgment is relevant to the evidentiary treatment of technical medical error, causation and the assessment of compensation.

It does not establish liability for synthetic biological products directly.

Polaris Legal Library

 

Case 2. Dubai Court of Cassation – Civil Appeal No. 377 of 2025

Judgment date: 28 August 2025.

Subject: Medical negligence and institutional responsibility.

Facts:

A patient underwent mini gastric bypass surgery and suffered serious complications, including permanent loss of stomach function.

The Medical Liability Committee identified gross medical negligence by the treating physician.

The Court considered the responsibility of the medical centre and other relevant healthcare parties.

Judicial principles:

Medical institutions may face civil responsibility for qualifying conduct of their physicians.

Employment and professional relationships are relevant to institutional responsibility.

The connection between professional conduct and the injury must be established.

Material and moral damage may be relevant to compensation.

Insurance and indemnity relationships must be distinguished from the injured person's underlying civil claim.

Application to synthetic biology:

If a biotechnology company operates a cell-therapy facility, it may face responsibility for qualifying misconduct by scientists or technicians working within its organisation.

The precise legal basis would depend on the relevant employment, supervision and statutory requirements.

Al Tamimi & Company+1

 

Case 3. Federal Supreme Court – Commercial Appeal No. 1273 of 2022

Judgment date: 28 February 2023.

Subject: Exceptional circumstances and contractual responsibility.

Facts:

A construction contractor failed to complete a government project on schedule during the COVID-19 pandemic.

The dispute concerned the financial consequences of delay and whether the exceptional circumstances affected contractual responsibility.

Judicial principles:

Exceptional events must be examined in their actual contractual context.

An event beyond the parties' control may affect responsibility for non-performance.

The consequences of the event must be examined.

Courts should not automatically reject a force-majeure defence without adequate reasoning.

Contractual liability and compensation must be assessed according to the circumstances.

Application to synthetic biology:

Suppose a biotechnology manufacturer cannot obtain essential biological inputs because of an unforeseeable international emergency.

This decision may help determine whether contractual non-performance should be excused or whether compensation remains payable.

However, it does not automatically excuse biosafety violations or statutory duties.

Polaris Legal Library

 

Case 4. Federal Supreme Court – Commercial Appeal No. 199 of 2022

Judgment date: 21 June 2022.

Subject: Contractor and engineer responsibility for latent building defects.

Legal issue:

The Court considered the time limit applicable to claims arising from building collapse or serious defects under the former Civil Transactions Law.

Judicial principles:

Special statutory liability may apply to defects that become apparent after completion.

The date on which the defect is discovered can be legally significant.

The claimant must establish the relevant defect and the applicable statutory basis.

Special limitation provisions may differ from ordinary contractual claims.

Application to synthetic biology:

The case provides an analogy for latent defects in engineered biological products.

For example, an engineered microorganism may appear stable during initial testing but develop an unexpected harmful characteristic after commercial release.

The analogy is useful in considering latent defects and limitation issues, although construction decennial liability cannot automatically be transferred to biotechnology products.

Polaris Legal Library

 

Case 5. Federal Supreme Court – Civil Cassation No. 880 of 2021

Judgment date: 15 November 2021.

Subject: Present damage, future damage and loss of opportunity.

Legal issue:

The dispute concerned compensation for financial and other legally recognised losses following a death, including future consequences and lost opportunities.

Judicial principles:

Compensation is not necessarily restricted to damage that has already fully materialised.

Sufficiently established future losses may be considered.

Loss of opportunity may constitute compensable damage where legal requirements are satisfied.

The claimant must establish the necessary connection between the harmful event and the claimed loss.

Application to synthetic biology:

An engineered biological product might cause a permanent medical condition requiring future treatment.

This judgment is relevant to assessing future medical expenses, future economic loss and other established consequences of biological injury.

Law Gratis+1

 

Case 6. Dubai Court of Cassation – Commercial Appeal No. 452 of 2017

Judgment date: 14 March 2018.

Subject: Contractual specifications and non-conformity.

Legal issue:

The dispute involved a discrepancy between the contracted and actual area of real estate.

The Court considered the importance of contractual specifications and the characteristics of the property delivered.

Judicial principles:

Contractual specifications are important in determining conformity.

The actual characteristics of the delivered subject matter must be examined.

Non-conformity may create contractual remedies.

The court must consider the terms of the agreement and applicable legal provisions.

Application to synthetic biology:

A biotechnology company may agree to manufacture an engineered enzyme with specified purity, stability or performance.

If the delivered product fails to meet those specifications, the purchaser may have contractual remedies.

This is an analogy concerning defective performance, not a biological-product liability precedent.

Law Gratis

 

Case 7. Abu Dhabi Court of Cassation – Commercial Appeal No. 700 of 2009

Subject: Material and moral damages.

Legal issue:

The dispute concerned the assessment of compensation for legally recognised material and non-material injury under the former Civil Transactions Law.

Judicial principles:

Material injury may give rise to compensation.

Moral harm may be separately recognised.

The assessment of compensation depends on the circumstances and evidence.

The legal relationship between the harmful conduct and the injury remains important.

Application to synthetic biology:

Suppose an unauthorised use of a person's genetic material causes financial loss and a serious invasion of personal privacy.

The principles governing material and moral injury may become relevant, alongside the specific requirements of the Human Genome Law and personal-data legislation.

This is an analogy concerning compensation and does not decide ownership of genetic material.

12. Case-law summary

Judicial authorityMain principleSynthetic biology application
Dubai Cassation 62/2025Medical error, causation and compensationInjury from engineered therapies
Dubai Cassation 377/2025Institutional responsibilityLaboratory and biotechnology company liability
Federal Supreme Court 1273/2022Force majeure and contractual responsibilityBiological supply-chain disruption
Federal Supreme Court 199/2022Latent defects and limitationHidden defects in biological products
Federal Supreme Court 880/2021Future damage and loss of opportunityLong-term genetic or medical injury
Dubai Cassation 452/2017Contractual conformityDefective engineered biological products
Abu Dhabi Cassation 700/2009Material and moral damagesGenetic privacy and personal injury

Again, these authorities provide analogical civil-law principles. None should be cited as a direct judgment on synthetic biology ownership.

13. Contractual ownership disputes in synthetic biology

Synthetic biology research frequently involves collaboration between universities, private companies, investors and independent scientists.

These relationships can generate complex ownership disputes.

A. Researcher versus university

A researcher develops a new engineered microorganism using university laboratory facilities.

Questions include:

Who owns the invention?

Who owns the physical biological samples?

Does the employment agreement allocate patent rights to the university?

Is the researcher entitled to additional compensation?

Who controls commercial licensing?

Article 10 of Federal Law No. 11 of 2021 is particularly relevant.

B. University versus biotechnology company

A university develops a biological technology using research funding from a commercial company.

The funding agreement may determine:

Patent ownership.

Commercial exploitation rights.

Research publication rights.

Confidentiality.

Licensing revenue.

Responsibility for regulatory compliance.

C. Investor versus biotechnology developer

An investor finances a synthetic biology startup.

The investment agreement should clarify whether the investor receives:

Shares in the company.

Rights to future royalties.

Rights to commercialise the technology.

Security over intellectual property.

Contractual rights concerning research milestones.

An investment in a biotechnology company does not automatically make the investor the owner of its biological inventions.

14. Civil remedies for synthetic biology disputes

Depending on the legal basis of the dispute, the available remedies may include:

RemedyExample
Monetary compensationPayment for biological contamination damage
InjunctionPreventing unauthorised use of patented technology
RestitutionRecovery of money obtained without legal justification
Contractual enforcementEnforcement of research or licensing agreements
Patent invalidationChallenging an improperly granted patent
Patent infringement reliefStopping unauthorised exploitation
Environmental remediationRestoring affected land or ecosystems
Regulatory suspensionStopping unauthorised biological activities
Data-related remediesAddressing unlawful disclosure or processing

The competent court and regulatory authority will depend on the legal basis, applicable jurisdiction and nature of the claim.

15. Hypothetical UAE synthetic biology civil-liability dispute

Consider the following hypothetical situation.

A biotechnology company in Abu Dhabi develops a genetically engineered microorganism for agricultural use.

The company obtains the organism from a university research project and begins commercial production.

During transportation, the organism escapes from a containment facility and contaminates neighbouring agricultural land.

Illustrative liability analysis

Research university

Questions concerning the original biological material, research agreements and intellectual property ownership.

Biotechnology developer

Potential responsibility under Article 16 of Federal Law No. 9 of 2020.

Manufacturer

Responsibility for manufacturing safeguards and regulated production activities.

Transport company

Potential statutory responsibility for damage caused by regulated transportation activities.

Agricultural property owner

Potential claims for physical damage, crop loss and legally recoverable economic losses.

Possible legal consequences

Civil compensation.

Environmental remediation.

Regulatory investigation.

Suspension of relevant permissions.

Contractual indemnity claims.

Intellectual property disputes.

This example illustrates how ownership, contractual rights, biosafety duties and civil liability can operate simultaneously.

16. Challenges in UAE synthetic biology law

Several important legal challenges remain.

1. Absence of a dedicated synthetic biology statute

The existing framework regulates several aspects of biotechnology, but it does not establish one comprehensive legal ownership system for every category of synthetic biological material.

2. Ownership of engineered organisms

The distinction between ownership of a physical organism and intellectual property in its genetic design requires careful legal treatment.

3. Uncertain long-term biological risks

Some engineered organisms may produce unexpected effects after prolonged exposure or environmental release.

4. Cross-border biological research

International biotechnology projects raise questions about genetic-resource permits, export approvals, contractual ownership and benefit-sharing.

5. Human genetic rights

Human genome research requires careful protection of consent, privacy and human dignity.

6. Patentability limitations

Some biological inventions are excluded from patent protection, while qualifying microbiological processes and products may receive protection.

7. Scientific causation

Biological damage may be difficult to trace to one particular developer, manufacturer, laboratory or transporter.

This creates challenges in proving causation and allocating responsibility among several participants.

17. Recommendations for strengthening the UAE framework

The following reforms could strengthen the UAE's synthetic biology governance.

Establish clearer statutory definitions of synthetic biological materials and engineered organisms.

Develop more detailed rules concerning ownership of engineered biological materials.

Improve contractual standards for university-industry biotechnology research.

Strengthen biological containment and environmental monitoring requirements.

Clarify liability allocation among developers, manufacturers, laboratories and transporters.

Establish appropriate insurance requirements for high-risk biological activities.

Improve procedures for genetic-resource benefit-sharing.

Strengthen protections governing human biological samples and genomic information.

Develop clearer rules for ownership and commercialisation of AI-designed genetic sequences.

Improve mechanisms for scientific expert evidence in biological injury litigation.

18. Important statutory references for academic research

Legal authorityRelevant provisions or subject
Federal Law No. 9 of 2020GMO biosafety
Article 16, Federal Law No. 9 of 2020Civil liability for GMO-related damage
Cabinet Resolution No. 84 of 2022GMO executive regulations
Federal Law No. 8 of 2021Access to genetic resources
Article 4, Federal Law No. 8 of 2021Access permits
Article 9, Federal Law No. 8 of 2021Benefit-sharing
Cabinet Resolution No. 32 of 2023Genetic-resource executive regulations
Federal Decree-Law No. 49 of 2023Human genome regulation
Article 16, Federal Decree-Law No. 49 of 2023Restrictions on human genomic alteration
Article 21, Federal Decree-Law No. 49 of 2023Genetic screening in civil-liability proceedings
Article 25, Federal Decree-Law No. 49 of 2023Genetic-data confidentiality
Article 28, Federal Decree-Law No. 49 of 2023Licensing of human-genome facilities
Federal Law No. 11 of 2021Industrial property and patent protection
Article 5, Federal Law No. 11 of 2021Patent eligibility
Article 7, Federal Law No. 11 of 2021Patent exclusions
Article 8, Federal Law No. 11 of 2021Inventorship
Article 10, Federal Law No. 11 of 2021Employee inventions
Federal Decree-Law No. 45 of 2021Personal Data Protection
Federal Decree-Law No. 25 of 2025Current Civil Transactions Law

19. Conclusion

Synthetic biology creates a new category of civil-law challenges involving biological ownership, intellectual property, environmental protection, human genetic rights and responsibility for scientific risks.

The UAE has established an important legislative foundation through Federal Law No. 9 of 2020, Federal Law No. 8 of 2021, Federal Decree-Law No. 49 of 2023 and Federal Law No. 11 of 2021.

Three principles are particularly important.

First: Ownership must be legally distinguished.

Ownership of biological samples, patent rights, genetic information and commercial exploitation rights are separate legal interests.

Second: Biological safety creates legal responsibility.

Article 16 of Federal Law No. 9 of 2020 expressly establishes civil liability for specified participants in regulated GMO-related activities.

Third: Scientific innovation must respect human and environmental interests.

Synthetic biological research must comply with applicable biosafety, genetic-resource, intellectual property, human-genome and personal-data legislation.

The seven judicial decisions examined provide relevant foundations for analysing medical injury, causation, institutional liability, defective products and compensation, although direct synthetic biology case law remains an important developing area.

Ultimately, the central principle of UAE synthetic biology civil law is that scientific innovation may create valuable intellectual property and commercial assets, but ownership and commercial exploitation cannot eliminate regulatory obligations or responsibility for legally attributable harm to individuals, property or the environment.

 

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT